secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2026-05-14T20:40:19+00:00
Accession:  0001171843-26-003429
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech Q2 net loss widens to $4.2M; progresses EB06 vitiligo Phase 2 prep
--------------------------------------------------------------------------------

- Net loss of $4.2M ($0.49/sh) for Q2 FY2026 vs $1.6M ($0.30/sh) in prior year.
- Operating expenses rose $2.7M to $4.3M on $2.3M R&D increase for EB06 and paridiprubart prep.
- Cash and cash equivalents $10.0M; working capital $8.2M as of March 31, 2026.
- EB06 Phase 2 vitiligo study on track; site activations and recruitment expected mid-2026 subject to approval.
- Paridiprubart Phase 3 ARDS data showed consistent treatment benefits across disease subgroups and comorbidities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/0001171843-26-003429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326003429/f8k_051326.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer